High-Risk and Oligometastatic Prostate Cancer Clinical Trials in Guangzhou, Guangdong

An Evaluation of the Efficacy and Safety of Apalutamide as Neoadjuvant Endocrine Therapy in High-Risk and Oligometastatic Prostate Cancer